tetano
Editor, Senior Moderator
J Clin Rheumatol
. 2025 Jun 23.
doi: 10.1097/RHU.0000000000002251. Online ahead of print. Adverse Effects Related to SARS-CoV-2 Vaccination in Patients With Rheumatic Diseases and Psoriasis From Argentina
Carolina A Isnardi[SUP] 1 [/SUP], Cecilia Pisoni[SUP] 2 [/SUP], Micaela Cosatti[SUP] 2 [/SUP], Karen Roberts[SUP] 1 [/SUP], Belén M Virasoro[SUP] 1 [/SUP], Jennifer Kreimer[SUP] 3 [/SUP], Cristina Echeverría[SUP] 3 [/SUP], María E D'Angelo[SUP] 4 [/SUP], Dora Pereira[SUP] 4 [/SUP], Ingrid Petkovic[SUP] 4 [/SUP], Yohana Soledad Tissera[SUP] 4 [/SUP], María Á Correa[SUP] 4 [/SUP], Gustavo Rodríguez Gil[SUP] 4 [/SUP], Rosana Quintana[SUP] 4 [/SUP], Karina Cogo[SUP] 4 [/SUP], Carla Alonso[SUP] 4 [/SUP], Nora Kogan[SUP] 4 [/SUP], Ana L Toledo[SUP] 4 [/SUP], M Agustina Alfaro[SUP] 4 [/SUP], Romina Nieto[SUP] 4 [/SUP], Lucila García[SUP] 4 [/SUP], Alejandra Rollano Perasso[SUP] 4 [/SUP], María E Debernardi[SUP] 4 [/SUP], Zaida Troyano[SUP] 4 [/SUP], Ingrid Strusberg[SUP] 4 [/SUP], Guillermo J Pons-Estel[SUP] 1 [/SUP], Emilce E Schneeberger[SUP] 5 [/SUP]
Affiliations
Background/objective: Patients with systemic rheumatic diseases were initially excluded from coronavirus disease 2019 (COVID-19) vaccine trials. Real-world data on vaccine safety in this population remain limited, particularly for non-mRNA vaccines. The aim of this study was to evaluate the safety of COVID-19 vaccines in patients with rheumatic diseases and/or psoriasis.
Methods: A longitudinal observational study including vaccinated patients ≥18 years old with rheumatic diseases and/or psoriasis vaccinated against COVID-19 was conducted. Adverse events (AEs) and disease flares were documented. Multivariable logistic regression analysis identified factors associated with AEs.
Results: Among 2160 patients with rheumatic diseases and/or psoriasis vaccinated against COVID-19 (3988 doses), 29.6% reported at least 1 AE, mostly mild/moderate flu-like symptoms and local hypersensitivity. AE incidence was highest for mRNA-1273 (316.7/1000 doses) and lowest for BBIBP-CorV (95.4/1000). Heterologous regimens and ChAdOx1 nCoV-19 as first dose were associated with increased AE risk, whereas BBIBP-CorV showed the opposite effect. Disease flares occurred in 2.5% of patients, predominantly arthritis and arthralgia, without association with any specific vaccines.
Conclusion: COVID-19 vaccines were generally well tolerated, with AE rates comparable to the general population. Heterologous regimens and vector-based and mRNA vaccines had higher AE incidence. These findings provide valuable safety data on vaccines used in Argentina and the region.
Keywords: COVID-19 vaccines; psoriasis; rheumatic diseases.
. 2025 Jun 23.
doi: 10.1097/RHU.0000000000002251. Online ahead of print. Adverse Effects Related to SARS-CoV-2 Vaccination in Patients With Rheumatic Diseases and Psoriasis From Argentina
Carolina A Isnardi[SUP] 1 [/SUP], Cecilia Pisoni[SUP] 2 [/SUP], Micaela Cosatti[SUP] 2 [/SUP], Karen Roberts[SUP] 1 [/SUP], Belén M Virasoro[SUP] 1 [/SUP], Jennifer Kreimer[SUP] 3 [/SUP], Cristina Echeverría[SUP] 3 [/SUP], María E D'Angelo[SUP] 4 [/SUP], Dora Pereira[SUP] 4 [/SUP], Ingrid Petkovic[SUP] 4 [/SUP], Yohana Soledad Tissera[SUP] 4 [/SUP], María Á Correa[SUP] 4 [/SUP], Gustavo Rodríguez Gil[SUP] 4 [/SUP], Rosana Quintana[SUP] 4 [/SUP], Karina Cogo[SUP] 4 [/SUP], Carla Alonso[SUP] 4 [/SUP], Nora Kogan[SUP] 4 [/SUP], Ana L Toledo[SUP] 4 [/SUP], M Agustina Alfaro[SUP] 4 [/SUP], Romina Nieto[SUP] 4 [/SUP], Lucila García[SUP] 4 [/SUP], Alejandra Rollano Perasso[SUP] 4 [/SUP], María E Debernardi[SUP] 4 [/SUP], Zaida Troyano[SUP] 4 [/SUP], Ingrid Strusberg[SUP] 4 [/SUP], Guillermo J Pons-Estel[SUP] 1 [/SUP], Emilce E Schneeberger[SUP] 5 [/SUP]
Affiliations
- PMID: 40548899
- DOI: 10.1097/RHU.0000000000002251
Background/objective: Patients with systemic rheumatic diseases were initially excluded from coronavirus disease 2019 (COVID-19) vaccine trials. Real-world data on vaccine safety in this population remain limited, particularly for non-mRNA vaccines. The aim of this study was to evaluate the safety of COVID-19 vaccines in patients with rheumatic diseases and/or psoriasis.
Methods: A longitudinal observational study including vaccinated patients ≥18 years old with rheumatic diseases and/or psoriasis vaccinated against COVID-19 was conducted. Adverse events (AEs) and disease flares were documented. Multivariable logistic regression analysis identified factors associated with AEs.
Results: Among 2160 patients with rheumatic diseases and/or psoriasis vaccinated against COVID-19 (3988 doses), 29.6% reported at least 1 AE, mostly mild/moderate flu-like symptoms and local hypersensitivity. AE incidence was highest for mRNA-1273 (316.7/1000 doses) and lowest for BBIBP-CorV (95.4/1000). Heterologous regimens and ChAdOx1 nCoV-19 as first dose were associated with increased AE risk, whereas BBIBP-CorV showed the opposite effect. Disease flares occurred in 2.5% of patients, predominantly arthritis and arthralgia, without association with any specific vaccines.
Conclusion: COVID-19 vaccines were generally well tolerated, with AE rates comparable to the general population. Heterologous regimens and vector-based and mRNA vaccines had higher AE incidence. These findings provide valuable safety data on vaccines used in Argentina and the region.
Keywords: COVID-19 vaccines; psoriasis; rheumatic diseases.